ArticleJMIR mHealth and uHealth2026
Use of Software as a Medical Device to Improve Therapeutic Adherence in Patients With Hematological Malignancies: Prospective Interventional MargheRITA Study.
Article in JMIR mHealth and uHealth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05260203 (Evaluation of Performance and Safety of APP RITA in Increasing the Therapeutic Adherence of Onco-Hematological Patients - a Prospective Monocentric Pre-Market Study with a Historical Group of Comparison), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Performance and Safety of APP RITA in Increasing the Therapeutic Adherence of Onco-Hematological Patients - a Prospective Monocentric Pre-Market Study with a Historical Group of Comparison
Who cites it
1 citing paper in PubMed.
- Health Literacy and Capecitabine Adherence in a Remote Monitoring Pilot Trial for Breast Cancer: Post Hoc Exploratory Analysis.JMIR formative research · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematological malignancies are a global health challenge, with a substantial number of deaths each year. Treatment adherence is crucial for improving patient outcomes in patients with hematological malignancies, but resource limitations and logistical challenges hinder optimal outpatient management. Digital health solutions such as the Remote Intelligence for Therapeutic Adherence (RITA) software as a medical device (SaMD) offer potential solutions by facilitating telemedicine visits and supporting patients in managing their treatment.
objectiveThe aim of this study was to evaluate the performance and safety of RITA SaMD in improving patient adherence to treatment protocols for hematological malignancies.
methodsThis prospective clinical investigation enrolled patients with hematological malignancies at Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo in Milan, Italy. The RITA SaMD group used the RITA platform, while the control group comprised historical patients. The primary end point was average therapeutic adherence to the prescribed drug treatment, measured as at least the 80% of the relative dose intensity, at month 3. Secondary end points were based on comparisons between the RITA SaMD group and the control group and included the average therapeutic adherence to the prescribed drug treatment at months 1 and 2, number of emergency room visits for minor and severe complications, and the average hospital stay. Multivariable logistic regression models were used to evaluate the effectiveness of RITA.
resultsBetween July and December 2022, 119 patients were included in the analysis (57 in the RITA SaMD group and 62 in the control group). At multivariable analysis, the probability of being adherent to treatment at month 3 in the RITA SaMD group was significantly higher than that in the control group (odds ratio 3.0, 95% CI 1.0-8.8; P=.04). A total of 1476 self-reported adverse events (AEs) were collected through RITA SaMD usage, the majority (N=1080) being grade 1 events. During the study visits, 20 AEs were recorded by the study physician (16 in the RITA SaMD group and 4 in the control group). Of the recorded AEs during study visits, 14 were serious AEs (11 in the RITA SaMD group and 3 in the control group). None of the reported AEs was considered related to RITA SaMD usage.
conclusionsThe MargheRITA clinical investigation showed that after 3 months of using RITA SaMD, patients with hematological malignancies had 3 times higher odds ratio of being adherent to the prescribed treatment than the control group. The use of RITA SaMD facilitated the reporting of AEs, reinforcing the role of mobile health apps and software in optimizing patient outcomes. Further research is needed to fully understand its interdisciplinary potential and long-term impact on patient outcomes.
trial registrationClinicalTrials.gov CTI05260203; https://clinicaltrials.gov/study/NCT05260203.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.